How to pick the right licensed producer of medical cannabis in Canada?

Interpreting the Access to Cannabis for Medical Purposes Regulations can be tough. That’s why Herb has prepared this handy guide to help you pick the right licensed producer of medical cannabis for you.

People turn to medical cannabis for various reasons over the course of their lives. From a strained muscle to anxiety, Parkinson’s to fibromyalgia, cannabis can be an alternative therapy for a variety of health issues.

Interpreting the Access to Cannabis for Medical Purposes Regulations can be tough and can leave people feeling confused, regardless of whether they are an experienced cannabis consumer or simply wanting to learn how cannabis can fit into their life.

There are over one hundred Licensed Producers of medical cannabis in Canada. One of the newest LP’s in the market – Solace Health – has recently launched the Solace Health Marketplace, a centralized destination for patients to access information and support regarding medical cannabis, as well as a diverse selection of cannabis products and accessories to support patient wellness.

With so many LPs in the market, and many more anticipated to enter, the options for the consumers are strong but the chaos of choice can sometimes be tough to navigate. That’s why Herb has prepared this useful guide to help you pick the right Licensed Producer for your medical cannabis needs.

Read the full article


SOURCE: Ophaug, D. (2018, April 25). Herb. How to pick the right licensed producer of medical cannabis in Canada? Retrieved from

See more from Herb.

A new survey asked workers across industries about their cannabis use.

That may be a fair (albeit rude) question, according to a new cannabis survey from Colorado. The recent survey, published by the federal Centers for Disease Control and Prevention (CDC), found restaurant and hotel workers have the highest rate of cannabis use among occupations. According to the results, 32 percent of restaurant and hotel employees admit to using cannabis.

The employees least likely to use marijuana are those working in education, public administration; mining, oil and gas; and healthcare, according to the cannabis survey. Fewer than 6 percent of workers in those occupations own up to weed use. Ten percent of transportation workers said they use marijuana.

“Reported current use of marijuana was lower in industries that are known to perform routine drug testing on employees such as the Healthcare and Social Assistance (7.4 percent); Utilities (5.8 percent); and Mining, Oil and Gas industries (5.2 percent),” wrote the public health team for the cannabis survey.

The weed survey showed cannabis use is more prevalent among those between 18 and 25 years old (29.6 percent) than people 26 to 34 (18.6 percent). More men (17.2 percent) than women (11.3 percent) said they use weed.

One of the major shortcomings of the CDC cannabis survey is that it doesn’t differentiate between people who smoke pot once a month and those who get high daily, reports Inverse. Another gap is that the cannabis survey doesn’t examine how many respondents actually get high on the job, reports ABC News. Future research will, no doubt, fill in those blanks.

Read the full article


SOURCE: Elliott, S. (2018, April 24). Herb. Which professionals smoke the most weed? Retrieved from

See more from Herb.

A Canadian company just bought 5 tonnes of cannabis oil from Israel

According to Reuters, a deal worth up to US$235 million was recently made between Globus Pharma and an unnamed Canadian company.

Together, an Israeli pharmaceutical company just solidified plans to sell 5 tonnes of cannabis oil to an unknown Canadian company. The deal is potentially worth hundreds of millions of shekels. A Together subsidiary, Globus Pharma will be in charge of the business dealings. The Canadian company involved remains under-wraps.

The arrangement will have the Canadian company purchasing 5 tonnes of cannabis oil (or 50 tonnes of dried inflorescences) per year from Globus and includes a research and development partnership to advance medical cannabis technologies.

With sales reaching an estimated US$3.17 – $4.7 per gram of inflorescence, the deal could be worth up to roughly US$235 million. The pricing scheme for the agreement will be based on the current Canadian marijuana market. Canada intends to fully legalize the adult use of recreational marijuana by this upcoming fall.

According to Reuters, the Canadian company hopes to obtain a license to market and sell medical cannabis domestically and abroad within the next four or five months.

Globus Pharma also has a deal with a German company for roughly half the quantity of inflorescences as this current deal. They also have an arrangement with another Canadian company for three tonnes of inflorescences per year.

Together, Globus’ parent company, is working on expanding its cannabis cultivation efforts as well, hoping to add 25 acres of greenhouses to their current operation.

Read the full article


SOURCE: Hoffman, R. (2018, April 23). Herb. A Canadian company just bought 5 tonnes of cannabis oil from Israel. Retrieved from

See more from Herb.

Epidiolex might be the first cannabis-based drug approved for epilepsy

Epidiolex, made by the United Kingdom-based GW Pharmaceuticals, might become the first FDA-approved drug for the treatment of epilepsy. Although cannabis has been used anecdotally for years to treat seizures, CBD and THC may finally get the regulatory stamp of approval.

There’s still much work to be done to discover the medical potential of cannabis. Research is still in its infancy, but doctors are trying to figure out the connections between marijuana and everything from concussions to cancer. One condition has always seemed to react positively to the use of CBD: epilepsy. Now, leading the pack, we may see a pot-based medication for epilepsy become the first approved by the FDA.

Epidiolex, made by the United Kingdom-based GW Pharmaceuticals, will face FDA review in June. And its prospects are promising. A panel of 13 advisors to the FDA unanimously suggested the drug be approved, examining medical trials and gauging the risk-benefit factors to prescribing the medication. Epidiolex contains no THC, and would not have any psychoactive effects.

There is a general consensus that cannabis-based treatments have an immensely positive effect on people struggling with epilepsy, even children. Some studies indicate that CBD oils can cut down on seizures by a whopping 50%. According to the epilepsy foundation, a third of patients are unsatisfied with their current treatment.

Read the full article from The Capital.


SOURCE: Kotzer, Z. (2018, April 22). Herb. Epidiolex might be the first cannabis-based drug approved for epilepsy. Retrieved from

See more from Herb.

The History of 4/20, The Marijuana Holiday

It all started with a Coast Guard sailor, a treasure map, and some high school students in San Rafael, California.

Every year on April 20th (4/20), cannabis lovers celebrate their favorite plant with festivals, protests, marches, and smoke-outs great and small.

But what are the origins of this high holiday? What does it mean? And where is it heading?

Our surprisingly well documented story begins in the fall of 1971 in San Rafael, California, when a group of wisecracking, weed-smoking students known as the Waldos got ahold of a treasure map.

Turns out one of the Waldos had a friend whose brother was in the Coast Guard at the time, stationed nearby at the Point Reyes Lighthouse. For years this Coast Guard cadet had been planting a small patch of pot in a forgotten area of federal land near the remote outpost, but as harvest approached this time around, he got paranoid about his commanding officer busting him.

So he drew a rough map showing where to search for the pot patch, and gave the Waldos permission to keep it all for themselves if they could find it before the weather turned or the buds rotted.

With this treasure map in hand, the Waldos met at 4:20 pm on a fateful autumn afternoon, under a statue of Louis Pasteur, to get high and gather their forces before setting out in search of the secret weed garden.

Read the full article from Leafly.

SOURCE: Bienenstock, D. (2018, April 18). Leafly. The Long, Strange History of 4/20, the Global Cannabis Holiday. Retrieved from

See more from Leafly.

MedReleaf adds PINs to its medical cannabis products to facilitate coverage and reimbursement under drug benefit plans

MedReleaf Corp. (TSX: LEAF) (“MedReleaf” or the “Company”), Canada’s first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced the introduction of Product Identification Numbers, or “PINs”, for 57 of its unique medical cannabis products including dried flower, oils and capsules.  With this announcement, MedReleaf continues to demonstrate leadership among Canadian licensed producers to facilitate the coverage of medical cannabis on employer-sponsored benefits plans.

Product Identification Numbers (PINs) are similar to traditional Drug Identification Numbers (DINs), designed to make it easier for employers and payers to classify and incorporate pharmaceutical and healthcare products into benefits coverage plans.

“Medical cannabis is being covered by an ever-increasing number of employers across Canada through health spending accounts and extended health benefits plans, but without an identification number for each product, it can be difficult to incorporate and track the use of our products within core health benefits programs,” said Robert, Gora, Senior Director of Physician Outreach. “Introducing PINs will help willing insurers and employers to list MedReleaf’s cannabis medicines on their formularies, improving access and cannabis drug coverage for patients across Canada.”

“We have extensive experience in developing programs to support large patient groups and we are encouraged by the growing interest we are seeing from employers and payers in covering medical cannabis products,” noted Neil Closner, CEO of MedReleaf. “Working with employers to update workplace drug and alcohol policies, providing guidance on benefit plan design, and now adding PINs to our industry-leading products, are all proof points of our commitment to leadership, innovation, and education regarding the therapeutic benefits of cannabis.”

SOURCE: (2018, April 16). MedReleaf Corp. MedReleaf adds PINs to its medical cannabis products to facilitate coverage and reimbursement under drug benefit plans. Retrieved from



Colorado sides with parents over doctors on medical marijuana for autism

Families spent hours with the state’s lawmakers convincing them that their kids need cannabis. 

Despite opposition from physicians and health experts, Colorado’s House of Representatives will now consider a bill which would add autism to the list of qualifying conditions for medical marijuana. After hearing from autism advocates, families and health experts for over five hours, a House committee voted on April 5 to allow the bill to come to a vote in the legislature.

The bill, which was introduced by Rep. Edie Hooton (D-Boulder and Gunbarrel), would allow adults as well as children under the age of 18 to treat symptoms of autism spectrum disorder (ASD), such as seizures, with the use of medical cannabis. For children, a prescription would have to be approved by two physicians.

If the bill passes, Colorado will join a number of other states which currently allow for the treatment of autism with medical marijuana. California, Oregon and Washington D.C. are among the jurisdictions which have fully legalized cannabis and list autism as a qualifying condition. Even states which have limited medical marijuana programs like Georgia have approved the treatment of autism with cannabis oils.

In Colorado, families are currently treating children who have been diagnosed with the disorder regardless of its legal status because of the effects they’ve seen firsthand. Several of those families appeared before lawmakers to testify in favor of the bill, including the Walker family from Texas.

Read the full article from The Capital.


SOURCE: TOMOSKI, M. (2018, April 16). Herb. Colorado sides with parents over doctors on medical marijuana for autism. Retrieved from

See more from Herb.

Colombia may soon supply the world with medical cannabis

PharmaCielo is paving the way for cannabis cultivation in Colombia. They are helping rural farming communities previously under the thumb of the exploitative guerrilla groups get into growing medical cannabis.

In 2016, Colombia’s government finally struck a peace deal with the Revolutionary Armed Forces of Colombia (FARC), the country’s largest guerrilla group, in a bid to de-escalate the country’s 53-year civil war. Major cities like Medellín, which once experienced astronomical homicide rates, have since become world-class innovation hubs and popular tourist destinations. They’ve also begun to attract international cannabis business.

One Canadian company based in Toronto, PharmaCielo, was the very first to obtain Colombia’s comprehensive cultivation license after President Juan Manuel Santos enacted a law in late 2016 legalizing medical marijuana. The company currently runs its principal cultivation facility out of Rionegro, a small city roughly an hour outside of Medellin, Colombia. But last year, PharmaCielo also announced a partnership with Cooperativa Caucannabis, a collective of small, rural and indigenous cannabis cultivators. This partnership has the potential to legitimize and stimulate the once illicit economies of rural farming communities previously controlled by the country’s exploitative guerrilla groups and paramilitaries.

The low cost of growing medical cannabis in Colombia has the potential to benefit medical patients in other countries as well, many of whom struggle to afford the exorbitant cost of marijuana in states like California or countries like Canada.

Read the full article from The Capital.


SOURCE: Hoffman, R. (2018, April 14). Herb. Colombia may soon supply the world with medical cannabis. Retrieved from

See more from Herb.

Anne Arundel County Medical Marijuana Land Use in Court

It could be a long night at Monday’s County Council meeting with several bills, including a handful of land use matters and a ban on variances for medical marijuana outlets, up for hearings.

Bill 24-18 would prevent any potential medical marijuana facilities from getting any variances to the tough limitations set in the law authorizing them.

Administrative hearings have allowed variances on four dispensaries in the county. But County Executive Schuh, who has fought to exclude and limit the medical marijuana industry from the county, replaced former Administrative Hearing Officer Doug Hollmann and installed Annapolis attorney Jonathan Hodgson.

Hodgson rejected a dispensary variance application in his first case on the issue.

Read the full article from The Capital.

SOURCE: Furgurson III, E.B.. (2018, April 15). The Capital. Anne Arundel County Council to hear testimony on medical marijuana, land use bills. Retrieved from

See more from The Capital.

Cannabis legalization can reduce violent crime.

A new study published in the Journal of Economic Behavior and Organization has added to an ever-growing body of research which suggests that cannabis legalization is linked to a decrease in violent crime. The study, conducted by researchers at the University of Bologna in Italy, looks at legalization’s effects on crime in the state of Washington.

The findings are the result of a comparison between Washington state, after it legalized in 2012, and the neighboring state of Oregon, which legalized two years later in 2014. That two-year gap allowed researchers to compare violent crime rates across several counties in both states and measure the effects of legalization.

The researchers cite four reasons they believe the legalization of cannabis may have had a positive effect on violent crime rates starting with the suggestion that legalization itself, “reduces the likelihood of [cannabis users and growers] engaging in violent activities.” They go on to say that legalization reduces the likelihood that those growing and selling cannabis will be involved in gang activity while the regulation of a legal market frees up police resources to combat other crimes.

The study also found that residents in legal states reduced their normal and binge alcohol consumption significantly when provided with the alternative of legal weed. Researchers see this reduction in the use of more “violence-inducing substances” like alcohol and cocaine as a contributing factor.

Read the full article from Herb.

SOURCE: Tomoski, M. (2018, April 9). Herb. New study confirms cannabis legalization reduces violent crime. Retrieved from

See more from Herb.